publication . Article . 2015

L’ÉTUDE CLINIQUE DU MOIS TECOS : confirmation de la sécurité cardiovasculaire de la sitagliptine

SCHEEN, André; PAQUOT, Nicolas;
Open Access French
  • Published: 01 Oct 2015
  • Country: Belgium
Summary : The cardiovascular safety of sitagliptin has been evaluated in TECOS («Trial Evaluating Cardiovascular Outcomes with Sitagliptin»). TECOS recruited patients with type 2 diabetes and a history of cardiovascular disease who received, as add-on to their usual therapy, either sitagliptin (n = 7.257) or placebo (n = 7.266), with a median follow-up of 3 years. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95 % confidence interval, 0.8...
free text keywords: Cardiovascular risk, Congestive heart failure, Sitagliptin, DPP-4 inhibitor, Type 2 diabetes, : Pharmacy, pharmacology & toxicology [Human health sciences], : Pharmacie, pharmacologie & toxicologie [Sciences de la santé humaine], : Endocrinology, metabolism & nutrition [Human health sciences], : Endocrinologie, métabolisme & nutrition [Sciences de la santé humaine]
Related Organizations
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue